Your browser is no longer supported. Please, upgrade your browser.
RAPT RAPT Therapeutics, Inc. daily Stock Chart
RAPT Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.05 Insider Own1.00% Shs Outstand23.27M Perf Week12.87%
Market Cap486.23M Forward P/E- EPS next Y-3.19 Insider Trans-7.83% Shs Float23.64M Perf Month44.28%
Income-46.90M PEG- EPS next Q-0.59 Inst Own76.20% Short Float0.64% Perf Quarter9.02%
Sales0.90M P/S540.26 EPS this Y-19.00% Inst Trans18.20% Short Ratio1.74 Perf Half Y-21.15%
Book/sh5.67 P/B3.60 EPS next Y-23.80% ROA- Target Price- Perf Year-
Cash/sh5.81 P/C3.52 EPS next 5Y- ROE- 52W Range10.52 - 51.21 Perf YTD-26.01%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-60.11% Beta-
Dividend %- Quick Ratio10.90 Sales past 5Y- Gross Margin- 52W Low94.20% ATR1.33
Employees68 Current Ratio10.90 Sales Q/Q- Oper. Margin- RSI (14)71.48 Volatility7.43% 7.63%
OptionableNo Debt/Eq0.00 EPS Q/Q-39.80% Profit Margin- Rel Volume1.82 Prev Close19.88
ShortableYes LT Debt/Eq0.00 EarningsApr 08 Payout- Avg Volume86.49K Price20.43
Recom2.00 SMA2022.98% SMA5022.32% SMA200-12.86% Volume157,244 Change2.77%
Jun-01-20Initiated H.C. Wainwright Buy $40
May-19-20Initiated Cantor Fitzgerald Overweight $37
Apr-13-20Initiated ROTH Capital Buy $38
Nov-25-19Initiated Wells Fargo Outperform $33
Nov-25-19Initiated UBS Buy $26
Nov-25-19Initiated BMO Capital Markets Outperform $35
May-29-20 08:00AM  
May-26-20 08:00AM  
May-19-20 07:47AM  
May-18-20 07:55AM  
May-17-20 10:38AM  
May-15-20 08:00AM  
May-14-20 08:00AM  
May-12-20 08:00AM  
Mar-30-20 08:00AM  
Mar-04-20 08:00AM  
Feb-19-20 08:00AM  
Feb-07-20 06:45AM  
Feb-04-20 05:43PM  
Jan-31-20 11:27AM  
Jan-07-20 08:00AM  
Dec-16-19 08:00AM  
Dec-11-19 08:00AM  
Dec-10-19 08:00AM  
Dec-04-19 08:00AM  
Dec-03-19 04:05PM  
Nov-11-19 10:56AM  
Oct-30-19 08:49PM  
Jul-30-19 03:25PM  
Jul-28-19 02:08PM  
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 2 portion of a Phase 1/2 clinical trial to evaluate as a monotherapy and in combination with pembrolizumab in patients with various types of charged tumors. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into allergically-inflamed tissues. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HO WILLIAMChief Medical OfficerJun 01Sale18.501,00018,50073,858Jun 02 05:49 PM
HO WILLIAMChief Medical OfficerMay 22Sale18.027,500135,15074,858May 22 08:14 PM
Brockstedt Dirk G.Chief Scientific OfficerMay 15Option Exercise6.189,87761,04020,133May 18 05:11 PM
Brockstedt Dirk G.Chief Scientific OfficerMay 15Sale15.009,877148,15510,256May 18 05:11 PM
Lam Karen CVP, Finance & ControllerMay 12Option Exercise1.862,7775,16513,610May 13 05:15 PM
Lam Karen CVP, Finance & ControllerMay 07Sale15.401,83128,19710,833May 08 05:34 PM